Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for SHR-A1811 and Pyrotinib Combo Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...
Shanghai Xinhengrui Medical Technology Secures Series A Funding for Heart Failure Device Development
Shanghai Xinhengrui Medical Technology Co., Ltd, a manufacturer of heart failure devices, has successfully raised...
Beyond Therapeutics Secures Tens of Millions in Pre-Series A Financing for Ophthalmology and Oncology Pipeline
Beyond Therapeutics Co., Ltd., a biotechnology company based in Suzhou with a focus on ophthalmology...
Mabwell Bioscience Receives NMPA Approval to Launch 9MW2921 Clinical Study
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it...
Centre Medical Secures Tens of Millions in Series A Financing to Expand Globally
Centre Medical, a Hong Kong-based cardiovascular specialized medical services provider, has reportedly raised tens of...
TransThera Sciences’ TT-00420 Receives Breakthrough Designation for Cholangiocarcinoma Treatment
The Center for Drug Evaluation (CDE) website has indicated that Nanjing-based TransThera Sciences (Nanjing), Inc.’s...
Shenzhen Salubris Pharmaceuticals’ SAL0120 for IgA Nephropathy Accepted for NMPA Review
Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced that the National Medical Products Administration...
NHSA Unveils 2023 Flying Inspection Plan for Medical Insurance Fund Oversigh
The National Healthcare Security Administration (NHSA) has released its 2023 Basic Medical Insurance (BMI) Fund...
Betta Pharmaceuticals’ MCLA-129 Combo Therapy for NSCLC Gets NMPA Clinical Approval
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced that it has received clinical trial...
Pfizer Launches Phase III Trial for Quadrivalent Influenza modRNA Vaccine in Argentina
Global pharmaceutical giant Pfizer (NYSE: PFE) has commenced recruitment in Argentina for a Phase III...
Zai Lab Initiates Phase III Trial for Bemarituzumab in First-Line Gastric Cancer Treatment
China-based biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced the first patient...
Chile Expands Financial Coverage for AbbVie’s RSV Prophylaxis Synagis
Chile’s Ministry of Health (MINSAL) has announced an immediate expansion in the coverage under its...
Silence Therapeutics Receives $4 Million Milestone Payment from Hansoh Pharmaceutical
UK-based Silence Therapeutics plc (NASDAQ: SLN) has announced the receipt of a $4 million milestone...
Harbour BioMed Reports First-Ever Profit in H1 2023 Interim Financial Results
Harbour BioMed (HKG: 2142), a biotech company with operations in Suzhou, China, Cambridge in the...
InnoCare Pharma and ArriVent Biopharma Partner on SHP2 Inhibitor and EGFR Inhibitor Combination
China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced a clinical development collaboration with US-based...
GSK’s Cabotegravir Receives NMPA Approval for HIV Treatment in China
The National Medical Products Administration (NMPA) has granted marketing approval for GlaxoSmithKline’s (GSK, NYSE: GSK)...
Beijing Tinavi Medical’s Knee Replacement Navigation System Approved by NMPA
Beijing Tinavi Medical Technologies Co., Ltd (SHA: 688277) has received marketing approval from the National...
GeneQuantum Healthcare and Aimed Bio Expand Partnership to Develop Five Novel ADC Drugs
China-based GeneQuantum Healthcare has unveiled a new agreement to expand its existing partnership with South...
BeiGene’s Brukinsa Receives US FDA Review for Relapsed/Refractory Follicular Lymphoma sNDA
China-based biotechnology company BeiGene (NASDAQ: BGNE) has announced that the US Food and Drug Administration...
AstraZeneca and Daiichi Sankyo’s Enhertu Gains New Indication Approval in China for HER2-Low Breast Cancer
Partners AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have announced that their co-developed...